Physician profile
Henry Townsend
NPI 1922114354
$738,233.69
in general payments reported to CMS, 2019-2025
46 companies · $136K in 2025
The $136K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170K · 2020: $65K · 2021: $86K · 2022: $115K · 2023: $93K · 2024: $74K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225K · Travel and Lodging: $44K · Consulting Fee: $20K · Food and Beverage: $15K · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $224,806.50 |
| Travel and Lodging | $44,026.98 |
| Consulting Fee | $19,560.00 |
| Food and Beverage | $14,774.21 |
| Education | $168.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236,449.85 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $235,673.64 | 2019-2025 | Evenity, Prolia, Enbrel |
| Janssen Biotech, INC. | $121,120.73 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Janssen Scientific Affairs, LLC | $58,640.86 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $29,051.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $18,952.21 | 2019-2024 | Orencia |
| Ucb, INC. | $14,501.96 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $9,335.59 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $7,011.43 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $1,298.90 | 2019-2025 | Benlysta, Arexvy, Shingrix |
| Radius Health, INC. | $698.30 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $635.35 | 2019-2025 | Taltz, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $625.46 | 2021-2025 | Saphnelo, Farxiga, Airsupra |
| Genentech USA, INC. | $479.68 | 2019-2023 | Actemra |
| Regeneron Healthcare Solutions, INC. | $434.81 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.